No takers for Genmab's zalutumumab

Genmab A/S (CSE:GEN) said it will wind down its zalutumumab program after failing to partner the cancer candidate. Last year, the biotech announced plans to partner the human mAb targeting EGFR as part of a revised corporate strategy to reduce operating expenses. The compound had missed the primary endpoint in a Phase III trial to treat squamous cell carcinoma of the head and neck (SSCHN) (see BioCentury, Nov. 8, 2010). ...